HUMA (Humacyte) Ending Cash Position: $80.26 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HUMA Humacyte Inc HUMA
21 GF Score
Price $0.60
! 6 Warning Signs
View Full Analysis

What is Humacyte Ending Cash Position?

Humacyte HUMA +9.93% 21 Ending Cash Position is $80.26 Mil as of Jun. 2026. GuruFocus rates HUMA with a GF Score™ of 21/100. The stock has 6 warning signs investors should review.

Humacyte's Ending Cash Position for the quarter that ended in Jun. 2026 was $80.26 Mil.

Humacyte's quarterly Ending Cash Position declined from Dec. 2025 ($50.85 Mil) to Mar. 2026 ($48.89 Mil) but then increased from Mar. 2026 ($48.89 Mil) to Jun. 2026 ($80.26 Mil).

Humacyte's annual Ending Cash Position increased from Dec. 2023 ($80.80 Mil) to Dec. 2024 ($95.29 Mil) but then declined from Dec. 2024 ($95.29 Mil) to Dec. 2025 ($50.85 Mil).

Humacyte Ending Cash Position Related Terms

Humacyte Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Humacyte's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Humacyte Ending Cash Position Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 217.50 149.77 80.80 95.29 50.85

Humacyte Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.39 19.84 50.85 48.89 80.26
HUMA
21GF Score
Humacyte Inc HUMA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Humacyte Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Humacyte's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=95.29+-44.44
=50.85

Humacyte's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=48.892+31.364
=80.26

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $80.26 Mil mean?
Humacyte (HUMA) has a Ending Cash Position of $80.26 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Humacyte and its competitors.
Is Humacyte's Ending Cash Position too high?
Humacyte's current Ending Cash Position is $80.26 Mil. Overall, Humacyte has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Humacyte's Ending Cash Position compare to CRBP and OKUR?
Humacyte's Ending Cash Position of $80.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Humacyte and its competitors. Humacyte's current Ending Cash Position is $80.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humacyte stock overvalued right now?
Humacyte (HUMA) has a current Ending Cash Position of $80.26 Mil. The current Ending Cash Position is $80.26 Mil. Humacyte's overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Humacyte (HUMA), the current Ending Cash Position is $80.26 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Humacyte Business Description

Address 2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
21GF Score

Get the complete analysis for HUMA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price